Article

Monitoring of human cytomegalovirus infections in heart transplant recipients by pp65 antigenemia.

Service de Chirurgie Cardio-Vasculaire et Thoracique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
Clinical Transplantation (Impact Factor: 1.63). 11/2003; 17(5):423-7. DOI: 10.1034/j.1399-0012.2003.00064.x
Source: PubMed

ABSTRACT Rapid diagnostic techniques offer the opportunity of early diagnosis of human cytomegalovirus (CMV) infection in immunocompromized patients at risk of developing CMV disease and syndrome. The use of CMV pp65 antigenemia as a predictor of CMV syndrome and disease in heart transplant recipient after induction therapy was studied retrospectively.
One hundred and nineteen consecutive heart transplant recipients treated with induction therapy who survived more then 14 d were monitored for CMV infection. Ninety-four recipients were seropositive for CMV. Twenty-five recipients were seronegative for CMV and received grafts from seropositive donors. Pre-emptive therapy was used in seropositive patients when CMV pp65 antigenemia was greater than 50 antigen-positive cells per 2 x 10(5) peripheral blood leukocytes (PBL); prophylactic therapy was done only in seronegative recipient matched with seropositive donor.
High-level CMV pp65 antigenemia (50 antigen-positive cells 2 x 10(5) PBL) occurred in 34% (41 of 119) of patients at a median of 44 d following transplantation. In seropositive recipients, 16% (15 of 94) of patients developed CMV invasive disease or syndrome, and in seronegative recipients 20% (5 of 25) of patients developed CMV disease or syndrome. Sixty-six per cent (62 of 94) of CMV seropositive patients were identified as not requiring pre-emptive therapy. In seropositive and seronegative recipients, the sensibility and negative predictive value of the cut-off level of 50 antigen positive cell for CMV disease and syndrome was 100%. The specificity was 79% and positive predictive value was 49%.
Because of the excellent sensibility and negative predictive value of the cut-off level of 50 antigen positive cell per 2 x 10(5) PBL, application of pre-emptive therapy guided by high level of CMV pp65 antigenemia in the context of induction therapy allow to omit antiviral therapy in many at risk patients. In the context of pre-emptive and prophylactic therapy, the cut-off level of 50 antigen positive cell do not allow to predict with accuracy the development of CMV disease or syndrome.

0 Bookmarks
 · 
55 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cytomegalovirus (CMV) is a common complication after heart transplantation, affecting almost half of all recipients. The clinical spectrum of this infection includes, in order of greater to lesser severity, latent infection, asymptomatic viremia, CMV syndrome and CMV disease. CMV is associated with rejection and vascular graft disease and is a major cause of morbidity and mortality. The factors most frequently involved in susceptibility to this infection and its severity are donor and recipient CMV serological status, the intensity of immunosuppression and the type of immunosuppressive agents used. The management strategies of this infection include universal or targeted prophylaxis, preemptive therapy and treatment of established disease. The use of preventive measures significantly reduces the incidence of symtomatic infection or CMV disease, which has been reported to be less than 3% in some recent series.
    Enfermedades Infecciosas y Microbiología Clínica 12/2011; 29 Suppl 6:52-5. · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: La infección por citomegalovirus (CMV) es una complicación importante del trasplante. La última década se ha caracterizado por los avances en su tratamiento, reduciendo su morbilidad y la mortalidad. Estos avances han sido decisivos en el diagnóstico y prevención. Se han desarrollado técnicas de diagnóstico rápidas y sensibles. Entre las estrategias de prevención destaca el uso correcto de los productos sanguíneos, las inmunoglobulinas y los fármacos antivirales, empleados en profilaxis o en terapia anticipada. El reciente desarrollo de fármacos eficaces por vía oral como el valganciclovir permitirá el tratamiento ambulatorio de los pacientes infectados. Es necesario trasladar este conocimiento a la práctica clínica diaria. Con este objetivo el Grupo de Estudio de la Infección en el Trasplante (GESITRA) de la Sociedad Española de Microbiología Clínica y Enfermedades Infecciosas (SEIMC) ha desarrollado este documento de consenso que incluye las últimas recomendaciones en el tratamiento de la infección por CMV postrasplante.
    Enfermedades Infecciosas y Microbiología Clínica 07/2005; 23(7):424–437. · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infections account for approximately 75% of all pulmonary complications in immunocompromised patients, and early and accurate diagnosis is essential because of associated high morbidity and mortality. The number of immunocompromised patients continues to increase because of greater use of immunosuppressive agents. Certain organisms are likely to cause infection with certain types of immunosuppression and during specific times during the course of immunosuppression. Knowledge of the acuity of the patient's illness, environmental exposures, nature of the underlying immune defect(s), and duration and severity of immunodeficiency can help the radiologist provide a more accurate differential diagnosis for the cause of pulmonary infection.
    Radiologic Clinics of North America 01/2014; 52(1):121-136. · 1.95 Impact Factor